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Abstract 
The present study was aimed at evaluating the possible use of inter polymer 
complexed (IPC) films of chitosan (CH) and carboxymethyl tamarind kernel 
powder (CMTKP) for colon release of budesonide. Viscosity analysis of the 
supernatant liquid obtained after reacting CH and CMTKP in different 
proportions revealed 40:60 to be the optimum stoichiometric ratio. The FTIR 
spectra of IPC films formed from 50:50 or 40:60 ratio of CH:CMTKP did not 
reveal any reduction in the peaks at 1560cm
−1 and 1407cm
−1 after exposure to 
pH 1.2, suggesting resistance of the interaction between –COO
− groups of 
CMTKP and –NH3
+ groups of CH to gastric pH. Tablets containing Avicel pH 
102 as diluent and coated to a weight gain of 10%, w/w with aqueous solutions 
of 40:60 or 50:50 ratio of CH:CMTKP did not release budesonide in pH 1.2 
buffer. Histopathology of the rat colon after oral administration of these IPC film 
coated tablets revealed significantly greater (p<0.05) reduction in TNBS-
induced ulcerative colitis as compared to that after administration of uncoated 
tablets. The Cmax of budesonide achieved after oral administration of these 
IPC film coated tablets was comparable to that observed after administration of 
uncoated tablets. The results strongly indicate versatility of CH-CMTKP IPC 
films to deliver budesonide in the colon. 
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Introduction 
Colon delivery for achieving either maximum drug absorption or local action is being 
extensively investigated over the past two decades. The main advantages associated with 
colon delivery is that the colon offers a near neutral pH, reduced digestive enzyme activity, 
a long transit time and increased responsiveness to absorption enhancers. However, due 
to its location at the distal part of the alimentary tract, the colon is particularly difficult to 
access. In addition, wide range of pH values and different enzymes present throughout the 
GIT, through which the dosage form has to travel before reaching the target site, further 
complicates the reliability and delivery efficiency. The classical approaches make use of 
polymers with pH-dependent [1] or pH-independent release characteristics [2]. Drug 
release in the former case is easily influenced by nature of diet. Further, physiologically, a 
highly alkaline pH of 7.4 of the small intestine often contributes to premature drug release 
and failure of the pH-dependent release systems before reaching the colon [3]. The pH-
independent release systems suffer from the drawback of incomplete drug release and 
have to be combined with other polymers that are either soluble at colonic pH or are 
capable of being degraded by colonic bacteria. 
The recent innovations make use of biodegradable polymer combinations that are cross 
linked with each other or with ions in order to render them insoluble in acidic pH. Cross 
linking of hydroxyl groups of guar gum with ester groups of trisodium triphosphate is 
reported to yield di-polymer phosphate ester type of interaction, which reduces the 
swelling of guar gum [4]. Carboxymethyl konjac glucomannan-chitosan polyelectrolyte 
beads have been reported for the delivery of protein delivery owing to its pH sensitive drug 
release [5]. 
CH is a linear polysaccharide obtained from deacetylation of chitin. Due to amino groups, it 
carries a net positive charge and can be easily cross-linked with other anions, oppositely 
charged drugs and polymers [6,  7] Beads prepared by cross linking CH with sodium 
alginate have been observed to protect drug release in stomach thus, serving as potential 
drug carriers for small intestine or colon [8]. 
Tamarind kernel powder (TKP) is derived from the seeds of Tamarindus indica Linn. 
commonly found in India and South East Asia. TKP is one of the cheapest gums available 
in India. However, because of several drawbacks, such as unpleasant odor, dull color, 
presence of water insolubles, low solubility in cold water, and fast biodegradability, its 
various derivatives e.g. acetyl, hydroxyalkyl and carboxymethyl [9,  10] have been 
prepared. Carboxymethyl tamarind kernel powder (CMTKP) is a carboxymethylated 
derivative of tamarind kernel powder. The incorporation of a carboxylic group imparts 
anionic character to CMTKP, thus allowing the formation of interpolymer complex between 
CMTKP and cationic polymers.  
Budesonide, a second generation glucocorticoid is used in the treatment of IBD. It has the 
highest affinity for glucocorticoid receptor as compared to other steroids (hydrocortisone, 
prednisolone, dexamethasone) and it does not reduce the cortisol levels. The pharmaco-
kinetic profile of budesonide favors a high topical efficacy because of rapid uptake by 
mucosal tissue and enhanced receptor binding properties [11]. In the light of these facts, a 
dosage form capable of delivering budesonide in a sustained manner during its transit   Chitosan-Carboxymethyl Tamarind Kernel Powder Interpolymer Complexation: …  59 
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through the lower part of GIT can be envisaged to provide a new paradigm in treating IBD 
more effectively. 
In the light of above facts, it was proposed to formulate colon release tablets of 
budesonide by coating them with aqueous mixtures containing CH and CMTKP in order to 
yield interpolymer complexed (IPC) film coated tablets. The characterization of the IPC 
films was done by FTIR studies. The effect of varying the composition of CH and CMTKP 
in the coating solution on the in vitro release of budesonide from tablets was investigated. 
Further, the formulated budesonide tablets were evaluated for their pharmacokinetic and 
pharmacodynamic performance after oral administration to rats. 
Results and Discussion 
Preparation and Characterization of CMTKP 
 
Fig. 1.   FTIR spectra of: CH powder (A), CMTKP powder (B); films prepared by 
interacting CH and CMTKP in the ratio of 70:30 (C), 60:40 (D), 50:50 (E), 40:60 
(F) or 30:70 (G) 
The prepared CMTKP was characterized by Fourier Transform Infra Red (FTIR) 
spectroscopy. The appearance of a peak at 1413 cm
−1 indicated the presence of –COO
− 
ions (representing C=O stretch of –COO
−) in the CMTKP specimen (Fig.1B). This peak 60  G. Kaur, S. Jain and A. K. Tiwary:   
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was absent in TKP sample thus, indicating that carboxymethylation had been successfully 
carried out. The degree of substitution was calculated according to the method described 
by Whistler, 1963 [12] and was found to be 0.2. 
Studies on CH-CMTKP complex 
Stoichiometry of the CH-CMTKP complex 
Fig. 2 shows the viscosity of the supernatants obtained after mixing solutions of CH with 
CMTKP solutions in different ratios. CMTKP bears a negative charge owing to the 
presence of –COO
− group introduced in CMTKP by carboxymethylation. CH bears a net 
positive charge due to presence of –NH3
+ groups. As a result, both polymers undergo 
spontaneous reaction when mixed together, resulting in formation of a solid mass. The 
viscosity of the supernatant obtained after mixing aqueous solutions of CH and CMTKP 
was observed to decrease as the proportion of CH in CH-CMTKP mixtures decreased. 
Moustafine et al. (2006) reported the viscosity to drop to minimum when the molar ratio 
between Eudragit E PO and Eudragit L 100-55 was unity [13]. The minimum viscosity of 
the supernatant obtained by reacting CH and CMTKP in the ratio of 40:60 indicated 
maximum interaction.  
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Fig. 2.   Viscosity of the supernatant obtained after centrifugation of admixed aqueous 
solutions containing different ratios of CH and CMTKP  
Characterization of CH-CMTKP IPC films 
Spectroscopic attributes 
Fig. 1 depicts the FTIR spectrographs of CH, CMTKP and IPC films formed by interacting 
various ratios of CH and CMTKP. It is evident from Fig. 1A that CH powder (85% 
deacetylation) exhibited a peak at 1560 cm
−1 indicating presence of –NH3
+ ions [14]. The 
peak at 1422 cm
−1 (Fig. 1A), suggesting presence of –COO
− ions could have arisen due to 
15% acetylation of CH powder. The FTIR spectrum of CMTKP (Fig. 1B) exhibited peaks at 
1413 cm
−1 suggesting the presence of –COO
− groups that were introduced by carboxy-
methylation of TKP. The IPC films formed by interacting different ratios of CH:CMTKP   Chitosan-Carboxymethyl Tamarind Kernel Powder Interpolymer Complexation: …  61 
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showed a peak at 1407 cm
−1 indicating the presence of –COO
− ions (representing C=O 
stretch of –COO
−). Further, the presence of a peak at 1560 cm
−1 could be ascribed to the 
existence of –NH3
+ (representing N-H stretch of –NH3
+) in CH molecule (Figs. 1C-G). 
Thus, the presence of –COO
− groups and –NH3
+ groups in the IPC films could be ascribed 
to the existence of NH3
+COO
− complex between CH and CMTKP molecules thus, leading 
to interpolymer complexation.  
 
Fig. 3.   FTIR spectra of IPC films containing different CH:CMTKP ratios after exposure 
to different pH media: 70:30 (pH 1.2) (A); 70:30 (pH 7.4) (B); 60:40 (pH 1.2) (C); 
60:40 (pH 7.4) (D); 50:50 (pH 1.2) (E); 50:50 (pH 7.4) (F); 40:60 (pH 1.2) (G); 
40:60 (pH 7.4) (H); 30:70 (pH 1.2) (I) or 30:70 (pH 7.4) (J). 
All these IPC films were exposed to pH 1.2 for 2 h followed by buffer pH 7.4 for 22 h. The 
peak at 1407 cm
−1 corresponding to –COO
− was observed to considerably decrease in 
intensity and the peak at 1560 cm
−1 corresponding to –NH3
+ ions was found to be 
completely abolished in the IPC films comprising of 70:30 ratio of CH:CMTKP after 
exposure to pH 1.2. This suggested total breakdown of COO
− NH3 
+
 linkages in these IPC 
films (Fig. 3A). The spectrographs were observed to be similar in nature after exposure of 
these films to buffer pH 7.4 (Fig. 3B). The spectrographs of IPC films containing 60:40 
ratio of CH:CMTKP showed reduced intensity of peaks at 1560 cm
−1 and 1407 cm
−1, thus 
indicating weakening of NH3
+COO
− interaction after exposure to acidic pH (Fig. 3C). 
Further, the –NH3
+ ion peak at 1560 cm
−1 disappeared completely after treatment with pH 
7.4 buffer for 22 h (Fig. 3D). The spectrograph of IPC film prepared by using 30:70 ratio of 
CH:CMTKP revealed absence of peak at 1560 cm
−1 after treatment with pH 1.2 and 7.4, 62  G. Kaur, S. Jain and A. K. Tiwary:   
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thus indicating complete breakdown of COO
−NH3
+ bonds (Fig. 3I,J). However, the IR 
spectrographs of films containing 50:50 (Figs. 3E and F) or 40:60 CH:CMTKP (Fig. 3G and 
H) did not reveal any change in the intensity of peaks at 1560 cm
−1 and 1407 cm
−1 after 
treatment with buffer 1.2 and 7.4. This indicated that carboxylate linkages in IPC films 
prepared from 50:50 or 40:60 were resistant to pH 1.2 and 7.4.  
Swelling Index determination 
The CH-CMTKP IPC films were found to exhibit swelling in acidic medium as well as in 
basic medium (Tab. 1). It is known that a decrease in charge density of the cross-linker 
decreases the cross-linking density, which leads to swelling. This swelling is favored by 
the protonation and repulsion of chitosan free ammonium groups. Highly acidic pH of the 
stomach dissociates the ionic linkages followed by dissolution of the network. This in turn 
is reported to result in fast drug release [15]. However, the IPCs exhibited considerably low 
swelling in pH 7.4. The swelling index was found to decrease to a limiting value when the 
CMTKP concentration was increased in the CH-CMTKP complex to 60%, w/w. However, 
further increase in CMTKP concentration increased the swelling index. The introduction of 
carboxymethyl groups in TKP has been reported to increase the swelling of TKP [16]. 
Thus, the IPC films comprising 30:70 ratio of CH-CMTKP showed increased swelling as 
compared to those containing 40:60 ratio of CH-CMTKP. 
Tab. 1.   Swelling indices of freshly prepared IPC films 
Swelling Index
a  Film Composition
(CH:CMTKP)  pH 1.2  pH 7.4 
70:30  2.56 ± 0.11  1.41 ± 0.07 
60:40  2.13 ± 0.10  1.16 ± 0.09 
50:50  1.57 ± 0.08  1.01 ± 0.05 
40:60  1.24 ± 0.05  0.89 ± 0.07 
30:70  2.18 ± 0.10  1.24 ± 0.04 
a Mean ± S.D of three experiments 
 
Physical Evaluation of Tablets 
The average weight of uncoated core tablets was 24.67 ± 1.10 mg. The acceptance value 
calculated was 11.98% which was well below the maximum 15% USP tolerance limit [17]. 
Hence, the tablets passed the weight variation test. Hardness of the tablets was 4.5 ± 0.5 
kg/cm
2 and friability was found to range from 0.36 to 0.46%, w/w. The axial and radial 
diameters, respectively, ranged from 1.75 to 1.80 mm and 3.98 to 4.02 mm. The uncoated 
tablets prepared by using 10%, w/w Eudragit L100-55 or CH:CMTKP as a binder started 
showing signs of cracking within 30 min of exposure to 0.1M HCl. 
The average weight of coated tablets was 27.20 ± 1.25 mg. The acceptance value 
calculated was 11.31%. Hence, the tablets passed the weight variation test. The axial and 
radial diameters of coated tablets, respectively, ranged from 2.02 to 2.08 mm and 4.01 to 
4.15 mm. Although, these tablets exhibited swelling, they didn’t soften or crack after 
exposure to 0.1M HCl for 2 h. 
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In vitro Drug Release Studies  
Release studies in buffer I.P. pH 1.2, buffer I.P. pH 7.4 and buffer I.P. pH 6.8 
The in vitro release of budesonide from the formulated tablets on sequential exposure to 
pH 1.2 (2 h), pH 7.4 (3 h) and pH 6.8 (19 h) is shown in Fig. 4. The uncoated tablets 
containing Eudragit L100-55 as binder released 24% budesonide in 2 h (pH 1.2). The 
remaining drug was released rapidly in pH 7.4 in 4 h. The tablets coated with 60:40 ratio of 
CH:CMTKP released 6% budesonide in pH 1.2. Additional 21% release was observed 
upon exposure of tablets to pH 7.4. The IR spectrographs of IPC films (Figs. 3C and D) 
containing 60:40 ratio of CH:CMTKP had showed a considerable reduction in the intensity 
of peaks at 1407 cm
−1 and 1560 cm
−1 indicating weakening of interaction between –NH3
+ 
groups of CH and –COO
− groups of CMTKP. 
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Fig. 4.   Release of budesonide from tablets containing Eudragit L100-55 alone as 
binder (uncoated) or after coating with IPC films comprising different ratios of 
CH:CMTKP in pH progression media, rat cecal contents or in presence of 
chitosanase 
The tablets coated with 50:50 or 40:60 ratio of CH:CMTKP did not release budesonide in 
pH 1.2. However, exposure to pH 7.4 released ~9% budesonide from tablets coated with 
50:50 ratio of CH:CMTKP. It is important to note that tablets coated with 40:60 ratio did not 
release budesonide at this pH The observation of <10% drug released in acidic media [17] 
indicated fulfillment of drug release criteria expected of enteric tablets. This was supported 
by the observation that there was no decrease in the intensity of the peaks characteristic 
of CH-CMTKP interpolymer complexation in the IR spectrographs of IPC films prepared 
from 50:50 (Figs. 3E and F) as well as 40:60 (Figs.3G and H) ratios of these polymers 64  G. Kaur, S. Jain and A. K. Tiwary:   
Sci Pharm. 2010; 78; 57–78. 
after their exposure to pH 1.2 or pH 7.4. Hence, the ability of the 50:50 or 40:60 
(CH:CMTKP) IPC film coating in restraining the release of budesonide from tablets can be 
attributed to the resistance of the complexation between –NH3
+ of CH and –COO
− of 
CMTKP to pH 1.2. It may be highlighted that the use of Eudragit L100-55 as binder could 
not control the release of budesonide from uncoated tablets. However, coating these 
tablets with CH-CMTKP (50:50 or 40:60) IPC films restrained the release of budesonide in 
pH 1.2. Hence, CH-CMTKP IPC films can be suggested to play a pivotal role in modulating 
the release behavior of the tablets.  
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Fig. 5.   Release of budesonide from tablets containing 50:50 or 40:60 ratio of 
CH:CMTKP as binder alone (uncoated) or coated with respective IPC film in pH 
progression media, rat cecal contents or in the presence of chitosanase 
The in vitro release profiles of budesonide from various batches of tablets containing 50:50 
or 40:60 ratio of CH-CMTKP as binder and coated with the respective ratio of their 
aqueous mixture on sequential exposure to pH 1.2 (2 h), 7.4 (3 h) and 6.8 (19 h) are 
depicted in Fig. 5. The uncoated tablets containing 50:50 or 40:60 ratio of CH:CMTKP as 
binder, released, respectively 52% and 50% budesonide in pH 1.2. Further, they released 
approximately 75% and 72% drug, respectively, in pH 7.4. This, indicated that a 
combination of CH:CMTKP when used alone as a binder (10% w/w) was not able to 
restrain the release of budesonide in stomach and small intestine. However, coating these 
tablets with the IPC films of respective ratio of CH:CMTKP restrained the release of 
budesonide in conditions mimicking stomach (pH 1.2). Further, the tablets containing 
50:50 ratio of CH:CMTKP as binder and coated with the same solution released 
approximately 9% budesonide in pH 7.4. These tablets released 28% budesonide in pH 
6.8 till 24 h. The tablets containing 40:60 ratio of CH:CMTKP as binder and coated with the 
same solution did not release budesonide in pH 7.4. The total budesonide released in pH   Chitosan-Carboxymethyl Tamarind Kernel Powder Interpolymer Complexation: …  65 
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6.8 after 24 h was found to be 16%. The release profiles of budesonide from tablets 
containing Eudragit L100-55 or CH-CMTKP as a binder and coated with respective 
CH:CMTKP (50:50 or 40:60) solution were not significantly different. 
Release studies in the presence of phosphate buffer I.P. pH 6.8 containing rat cecal 
contents or chitosanase enzyme 
The release profiles of budesonide from CH-CMTKP coated tablets containing Eudragit 
L100-55 or CH-CMTKP solution as binder on sequential exposure to pH 1.2, 7.4 and 6.8 
containing rat cecal contents are depicted in Figs. 4 and 5. The release of budesonide in 
the presence of rat cecal contents in the dissolution medium was significantly (p<0.05) 
increased as compared to that in its absence. The in vitro drug release from tablets 
containing Eudragit L100-55 as binder and coated with 60:40, 50:50 or 40:60 ratio of 
CH:CMTKP after 24 h in the presence of rat cecal contents was enhanced to 99%, 70% or 
59%, respectively, from 84%, 36% or 25% in the absence of rat cecal contents (Fig. 4). 
The final exposure of tablets containing 50:50 ratio of CH:CMTKP as binder and coated 
with the same solution to rat cecal contents released 74% budesonide as compared to 
30% in the absence of rat cecal contents. Similarly, the tablets containing 40:60 ratio of 
CH:CMTKP as binder and coated with the same solution showed an increase in the 
release of budesonide from 19% to 60% in the presence of rat cecal contents (Fig. 5). The 
increase in the budesonide release in the presence of rat cecal contents demonstrated the 
vulnerability of CH:CMTKP IPC to the polysaccharidases present in the colon. Although, 
the presence of rat cecal contents in the dissolution media enhanced the amount of 
budesonide released, complete release of budesonide was not observed even after 24 h 
(Figs. 4 and 5) from tablets coated with CH:CMTKP 50:50 or 40:60. This could be due to 
the reduction in the activity of polysaccharidases when used over long duration of time 
during  in vitro testing. A logical approach for releasing more amount of drug from 
polysaccharide-based drug delivery systems is to use higher concentrations of rat cecal 
contents in the dissolution medium. Li-Fang et al., (2009) have reported 60% theophylline 
release from chitosan/Kollicoat SR 30D coated tablets in the presence of 4%, w/v rat cecal 
contents [18]. Tavakol et al. (2009) used 20%, w/v rat cecal content and observed an 
increase in the amount of sulfasalazine released from chitosan coated calcium alginate 
beads. The increase in the amount of sulfasalazine released was found to be less for the 
tablets coated to higher weight gain [19]. The quantity of fecal matter in humans to which 
the dosage form might be exposed is manifolds greater than what was used in the present 
study. Hence, incomplete release of budesonide in the presence of rat cecal contents 
during these in vitro dissolution studies is not unexpected [20]. 
The presence of chitosanase increased the amount of budesonide released from the 
coated tablets. The final exposure of tablets coated with 50:50 or 40:60 ratio of 
CH:CMTKP to pH 6.8 containing chitosanase for 19 h enhanced the amount of 
budesonide released from tablets containing Eudragit L100-55 as binder to 92.43% and 
83.25% as compared to 70.5% and 59.8%, respectively, in the presence of rat cecal 
contents (Fig. 4). Similarly, the presence of chitosanase in the dissolution media increased 
the release of budesonide from the tablets coated with IPC film comprising 50:50 or 40:60 
ratio of CH:CMTKP containing respective ratio of CH:CMTKP as binder to 89% and 83% 
as compared to 74% and 57%, respectively, in the presence of rat cecal contents (Fig. 5). 
The availability of the free amino group in CH is a prerequisite for its hydrolysis by 
chitosanase enzyme [21]. However, since the amino group of CH molecule is ionically 66  G. Kaur, S. Jain and A. K. Tiwary:   
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complexed with –COO
− groups of CMTKP, complete hydrolysis of CH can not be 
expected. This seems to be responsible for incomplete (∼90%) budesonide release from 
IPC film coated tablets. 
Mechanism and kinetics of drug release from coated budesonide tablets 
The release kinetics of budesonide from tablets containing Eudragit L100-55 or CH-
CMTKP solution as binder and coated with 50:50 or 40:60 ratio of CH:CMTKP was 
analyzed by Korsmeyer–Peppas model [22]. The value of r
2 was found to lie above 0.9 in 
all the cases. The value of release exponent was more than 1.0 in all the cases, indicating 
that the drug release can be ascribed to a Super Case II transport. Super Case II transport 
is reported to be exhibited when diffusion and relaxation rates are comparable [23, 24]. 
The main reason for this observation is erosion of the polymers. However, release of 
budesonide from these tablets was observed to follow zero order kinetics during sequential 
exposure of tablets to progressive pH media, rat cecal contents and in presence of 
chitosanase enzyme (Tab. 2). Hence, it can be suggested that the interpolymer 
complexation between CH and CMTKP was resistant to different pH media and release of 
budesonide occurred due to slow erosion of polymers.  
Tab. 2.   Release kinetics of budesonide from tablets containing Eudragit L100-55 or 
CH:CMTKP as binder and coated with respective CH-CMTKP IPC films 
Binder  Coat  DM*  Korsemeyer and Peppas 
equation 
    r
2  Order of Release 
A  0.9451  Super Case II 
B  0.9534  Super Case II  CH:CMTKP 
50:50  C  0.9743  Super Case II 
A  0.9763  Super Case II 
B  0.9528  Super Case II 
Eudragit 
L100 55  CH:CMTKP 
40:60  C  0.9778  Super Case II 
A  0.9127  Super Case II 
B  0.9690  Super Case II 
CH:CMTKP 
50:50 
CH:CMTKP 
50:50 
C  0.9760  Super Case II 
A  0.9760  Super Case II 
B  0.9675  Super Case II  CH:CMTKP 
40:60 
CH:CMTKP 
40:60  C  0.9742  Super Case II 
* Dissolution Media; A: pH progression media; B: In rat cecal contents; C: In 
presence of chitosanase 
 
Stability Studies 
The tablets coated with 50:50 or 40:60 ratio of CH:CMTKP containing Eudragit L100-55 or 
CH-CMTKP as binder were found to exhibit complete physical and chemical stability on 
storage at 40°C/ 75% RH. There was no change in the color and weight of the tablets. The 
value of f1 was found to be 2.98 and that of f2 was found to be 95.63, this indicated that 
the coated tablets were not affected adversely on storage. 
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Pharmacokinetic studies 
In vivo drug release  
The plasma concentration time profiles of budesonide uncoated tablets as well as of 
tablets coated with 50:50 or 40:60 ratio of CH:CMTKP containing respective CH-CMTKP 
solution or Eudragit L100-55 as binder following oral administration to rats is depicted in 
Fig. 6. The uncoated budesonide tablets containing Eudragit L100-55 as binder released 
budesonide within 1 h of administration, suggesting that Eudragit L100-55 alone was not 
able to delay the drug release. The plasma concentration of budesonide was found to rise 
quickly after administration of uncoated tablets and Cmax of 1091.99 ng/ml was achieved 
in 2 h. However, after administration of tablets containing Eudragit L100-55 or CH-CMTKP 
solution as binder and coated with 50:50 or 40:60 ratio of CH:CMTKP, budesonide was 
detectable in plasma after 2 h of administration. The time to achieve Cmax after oral 
administration was delayed to 8 h for coated tablets. This strongly indicated that the IPC 
films were able to inhibit the release of budesonide in gastric pH. However, the plasma 
budesonide concentration in rats administered with coated tablets (50:50 or 40:60 ratio of 
CH:CMTKP) rose steadily after 4 h and then declined after 8 h thus suggesting that the 
polymers were susceptible to degradation by the polysaccharidases present in the colon.  
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Fig. 6.   Pharmacokinetic profile of budesonide following oral administration of tablets 
containing Eudragit L100 55 as binder without coating; coated with aqueous 
solution containing CH:CMTKP in the ratio of 40:60 or 50:50; containing 
CH:CMTKP (40:60) as binder and coated with the same solution or containing 
CH:CMTKP (50:50) as binder and coated with the same solution. 
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A comparison of rate (Tmax) as well as extent (AUC) of budesonide absorbed from tablets 
coated with CH-CMTKP IPC films containing Eudragit L 100-55 as binder or those 
containing CH-CMTKP solution as binder did not reveal any significant difference (p<0.05) 
(Tab.3). This indicated that CH-CMTKP solution as binder performed in a manner similar 
to Eudragit L100-55 
Tab. 3.   Pharmacokinetic parameters of budesonide tablets containing Eudragit L100-55 
as binder and coated with CH-CMTKP IPC films 
Pharmacokinetic parameters  Binder Coat 
Tmax (h)  Cmax (ng/ml)  AUC 
Uncoated  2  1091.9 ± 218.38  5019 
CH:CMTK
P 50:50  8  998.21 ± 229.98  8882  Eudragit 
L100 55 
CH:CMTK
P 40:60  8  1009.63 ± 203.6  11531 
CH:CMTKP 50:50  CH:CMTK
P 50:50  8  1012.65 ± 263.36  9355 
CH:CMTKP 40:60  CH:CMTK
P 40:60  8  1045.54 ± 203.67  11816 
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The Colon/Body weight (C/B) ratio in rats was calculated for quantitative evaluation of the 
inflammatory colitis. The C/B ratio after intracolonic administration of TNBS was 
significantly more as compared to the group receiving normal saline (p<0.05). The C/B 
ratio after oral administration of uncoated or IPC film coated budesonide tablets containing 
Eudragit L 100-55 or CH-CMTKP (40:60) as binder was significantly decreased (p<0.05) 
as compared to the TNBS-induced colitis groups (Fig. 7). Further, a better therapeutic 
effect was observed after administration of coated budesonide tablets as compared to 
uncoated budesonide tablets. This could be attributed to the release of budesonide in 
colon from the coated tablets. The five day administration of coated tablets (40:60; 
CH:CMTKP) could not reduce the C/B ratio in the TNBS induced colitic rats to a level 
comparable to normal rats. Nevertheless, the coated tablets were almost 2-fold more 
effective than uncoated tablets. 
Histopathological studies 
 
Fig. 8.   Light microscopic photographs of colon: normal colon (A); TNBS induced 
ulcerative colon (B); after treatment with : uncoated budesonide tablets 
containing Eudragit as binder (C); coated budesonide tablets containing 
Eudragit as binder and coated with 40:60 ratio of CH:CMTKP IPC film (D); 
coated budesonide tablets containing CH:CMTKP (40:60) as binder and coated 
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Fig. 8 shows the histology of normal colon. The four layers of colon wall are mucosa, 
submucosa, muscularis externa and serosa. The section of the colon shows temporary 
folds of the mucosa and submucosa (Fig. 8A). As is evident from Fig 8B, the ulcerative 
colitis induced colon showed shedding of epithelium and lymphocytic infiltration in lamina 
propria. The inflammation was spread over the mucosa, submucosa, muscle layer and 
serosa. Oral administration of budesonide tablets containing Eudragit L 100-55 or CH-
CMTKP as binder and coated with 40:60 ratio of CH:CMTKP resulted in a marked 
decrease in the extent and severity of colonic damage. The histopathological features of 
colon clearly indicated that the morphological disturbances associated with TNBS 
administration were corrected after five days of oral administration of these tablets (Figs. 
8D and E). However, in rats treated with uncoated tablets containing Eudragit L100-55 as 
binder, lymphocytic infiltration as well as broken and intact epithelial lining was evident 
(Fig. 8C), suggesting decreased effectiveness of uncoated budesonide tablets in rectifying 
the ulcerative colitis induced by TNBS administration.  
Conclusion  
The results of the present investigation revealed distinct advantage of coating tablets with 
IPC films containing 50:50 or 40:60 ratio of CH:CMTKP as compared to uncoated tablets 
granulated with Eudragit L100-55 or CH-CMTKP solution in restraining the in vitro release 
of budesonide in gastric pH. These tablets released budesonide under conditions 
mimicking large intestine in zero order fashion through 19 h during dissolution studies. 
Although, the release of budesonide in rats was delayed, the peak plasma concentration 
was comparable to that obtained after oral administration of uncoated tablets. The ability of 
the IPC films in providing the observed release characteristics to budesonide core tablets 
was correlated with the ability of –NH3
+ groups of CH to form complex with –COO
− groups 
of CMTKP and the stability of these complexes in acidic media. The use of enteric polymer 
as binder offers no advantage for protecting the drug release in stomach. The tablets 
coated with 40:60 ratio of CH:CMTKP can be envisaged to offer a great promise for colon 
delivery of budesonide, thereby providing drug concentration in the distal part of 
gastrointestinal tract for longer durations for effective therapy of IBD. 
Experimental 
Materials 
Budesonide was received as a gift sample from Ranbaxy Research Labs, Gurgaon, India. 
TKP was received as gift sample from Encore Natural Polymers Pvt. Ltd., Ahmedabad, 
India. CH was purchased from Indian Sea Foods Ltd., Cochin, India. Chitosanase (Product 
No. C9830, enzyme activity 192.68 units/mg) was purchased from Sigma-Aldrich, Mumbai, 
India. Ammonium acetate, acetic acid were of analytical grade and were purchased from 
Qualigens Fine Chemicals, India. Acetonitrile and potassium dihydrogen orthophosphate 
of HPLC grade were purchased from Merck India, Ltd. All reagents and chemicals were of 
analytical grade and used as received. 
Procedure for carboxymethylation of TKP and Characterization by IR 
Carboxymethylation of TKP was carried out using the method reported by Goyal et al. [25]. 
TKP (0.05 mol) was dispersed in 80 ml alkaline aqueous methanol (0.158 mol sodium 
hydroxide). To this dispersion monochloroacetic acid (0.09 mol) was added in solid form   Chitosan-Carboxymethyl Tamarind Kernel Powder Interpolymer Complexation: …  71 
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with continuous stirring for 15 min. The flask was immersed in a thermostatic water bath 
and the temperature was maintained at 70°C for 60 min. The contents of the flask were 
shaken occasionally during the course of the study. The reaction product was filtered, 
dissolved in water and neutralized with dilute acetic acid. The reaction product was 
precipitated in ethyl alcohol and washed twice with aqueous methanol (80 %, v/v) followed 
by pure methanol. The products were initially dried at room temperature and then in 
vacuum oven at 40°C for 4 h to obtain carboxymethyl tamarind kernel powder (CMTKP). 
The degree of substitution of CMTKP was determined by titrimetric method [12]. The 
CMTKP was characterized by FTIR analysis.  
Studies on CH-CMTKP Complexes 
Stoichiometry of the polymer complexes 
CH solution was prepared in 1.5% v/v acetic acid. CMTKP solutions were separately 
prepared by hydrating them in distilled water. Both the solutions were at 25°C to obtain 
80:20, 70:30. 60:40, 50:50, 40:50, 30:70 and 20:80 ratio of CH:CMTKP. The samples were 
incubated at 37°C for 24 h. The samples were then centrifuged at 15000 rpm. The 
viscosity of the supernatant solution was determined using Brookefield RVDV II Pro 
Viscometer, UK (Spindle 21). 
Preparation of CH-CMTKP interpolymer complexed films 
CH (375 mg) was dissolved in 15 ml solution of 3%, v/v acetic acid. To this mixture 8 ml of 
5 M-ammonium acetate was added. CMTKP (375 mg) was separately dissolved in 7ml 
distilled water and slowly added with stirring to CH solution. This mixture was poured in 
petriplates and dried at 50 °C for 48 h. Films with a total polymer content of 2.5%, w/v 
containing 70:30, 60:40, 50:50, 40:60 or 30:70 ratio of CH:CMTKP were prepared using 
this method. The dried films were stored in a desiccator until use.  
Characterization of IPC films 
FTIR analysis 
CH, CMTKP and IPC films formed by drying admixtures containing different ratios of 
CH:CMTKP were subjected to FTIR analysis (Perkin Elmer RXI, USA). The fresh films 
were sequentially exposed to pH 1.2 buffer IP for 2h and pH 7.4 buffer IP for 22 h. The 
exposed films were dried at 50°C for 24 h and subjected to FTIR analysis. 
Swelling Index Measurement 
The swelling index of the IPC films after exposure to different pH was determined by 
sequentially immersing the films in pH 1.2 for 2 h and pH 7.4 for 22 h. The swelling index 
was calculated according to the formula 
1
1 2
W
W W
Index Swelling
−
=  
Where, W1 is the initial weight of the film and W2 is the weight of the swollen film. 
Preparation of core Tablets 
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granulation technique. Budesonide and Avicel
® pH 102 were granulated using Eudragit
® 
L100-55 (alcoholic solution) or CH:CMTKP solution (10% w/w) as binder. The granules 
were passed through #16 and dried at 50 ± 2°C to 2–3% w/w residual moisture content. 
The dried granules were passed through #20 sieve and fines were retained on #44 sieve. 
10%, w/w of fines was mixed with the granules. Magnesium stearate (1%, w/w) was added 
to the granules. Tablets were compressed using biconvex punches in a six station rotary 
tablet compression machine (A K Industries, M207, Nakodar, India). These tablets were 
tested for dimensions (axial and radial diameters), hardness, friability and weight variation. 
Testing of uncoated tablets 
The axial and radial diameters of ten compressed tablets of each batch were determined 
by using electronic digital vernier calipers. Hardness of ten tablets was determined with the 
help of Pfizer hardness tester (Campbell Electronics, Mumbai). The friability test, weight 
variation test and disintegration test were performed in accordance with the method 
prescribed in USP 30, NF 25 [17]. 
Coating of budesonide tablets 
The formulated budesonide tablets containing Eudragit L100-55 or CH:CMTKP solution as 
binder were coated with aqueous solutions containing different CH:CMTKP ratios 
(Composition same as IPC film) to obtain a weight gain of 10%, w/w. The total polymer 
concentration was kept constant at 2.5%, w/v. A separate batch of compressed tablets 
was coated with 2.5%, w/v solution of CH. The coating solution was sprayed at a rate of 5 
ml/min with the help of peristaltic pump using a spray gun of 1 mm nozzle (Electrolab, 
PP201V, Mumbai, India) in a coating pan (12"diameter) being rotated at 18 rpm (AK 
Industries, M1107, Nakodar, India). Compressed air was introduced at a pressure of 1.5 
kg/cm
2. The inlet air temperature was maintained at 60°C. The inner surface of coating 
pan was modified by attaching inert tubes (8 mm diameter) from the centre to the 
periphery for easy rolling of tablets thereby ensuring efficient mass transfer of polymer. 
The coated tablets were also evaluated for weight variation, disintegration time. Further, 
the axial and radial diameters were measured as described above. 
In vitro release kinetics of budesonide from coated tablets 
In vitro release of budesonide from coated tablets was evaluated out using USP 30-NF25 
(Dissolution Apparatus 1-basket method) utilizing temperature of 37±0.5°C with constant 
stirring rate of 50 rev/min in a pH progression media containing 0.5% v/v Tween 20 [26] to 
maintain sink conditions. pH progression consisted of exposure of tablets to buffer pH 1.2 
IP for 2 h followed by buffer pH 7.4 IP for 3 h and buffer pH 6.8 for further period of 19 h. 
Dissolution studies were also carried out in pH 1.2 (2 h), pH 7.4 (3 h) followed by pH 6.8 
(19 h) containing rat cecal contents (4%, w/v) or chitosanase to check the vulnerability of 
the CH-CMTKP IPC films to polysaccharidases produced by the colonic bacteria. The 
chitosanase (192.68 units/mg) was dissolved in sodium acetate (50 mM) buffer pH 5.5 to 
yield a solution containing 0.05 units of chitosanase in 100 ml of dissolution media. These 
solutions were prepared immediately before use. Aliquots (5 ml) from the dissolution 
media were withdrawn at predetermined intervals and immediately analyzed for 
budesonide using HPLC. An equal volume of respective buffer containing Tween 20 
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HPLC analysis 
The samples obtained from dissolution studies were filtered through 0.45 µ nitrocellulose 
filters (Millipore, USA) and manually injected (20 µL) using Rheodyne injector for HPLC 
analysis. The stationary phase consisted of C8 column (150 mm×4.6 mm, 5 μ). Acetonitrile 
and 25 mM phosphate buffer (pH 3.2) in the ratio of 60:40 v/v at a flow rate of 1 ml/min 
served as mobile phase [27]. Data acquisition and processing was performed by using 
Empower 2 software (Waters, Austria). 
Mechanism and Mathematical Modeling for Drug Release 
The mechanism of drug release during dissolution studies in pH progression media, in the 
presence of rat cecal contents or in the presence of chitosanase was evaluated by using 
the Korsmeyer equation 
n Kt
M
Mt
=
∞
 
Where,  
Mt/M∞ = fractional release of drug, 
t = release time,  
k = kinetic constant, which incorporates structural and geometric characteristics of the 
device 
n = release exponent, which indicates the kinetic release. 
When the exponent n takes a limiting value of 0.45, it is the case of diffusion-controlled 
drug release (Fickian release). Case II transport or relaxation controlled delivery; the 
exponent n is 0.89 for release from cylinders. Values of n between 0.45 and 0.89 can be 
regarded as an indicator for the non-Fickian release or anomalous transport. The non-
Fickian kinetics is regarded as couple diffusion/polymer relaxation. In addition, Super Case 
II kinetics is followed when the values of n are greater than 0.89 [22]. 
Stability studies 
The tablets coated with 50:50 or 40:60 ratio of CH:CMTKP were sealed in glass vials and 
stored under 45°C/ 75% RH for 6 month. Tablets were taken out after every 15 days and 
evaluated for weight variation, disintegration time, and in vitro drug release. The 
dissolution data of stored tablets was compared with that of freshly prepared tablets by f1 
(dissimilarity) and f2 (similarity) analysis. 
Pharmacokinetic studies 
Spargue-dawley rats of either sex weighing 200–300 g maintained on normal diet were 
used for this study. Rats were divided into seven groups. Each group comprised of four 
rats for generation of data in one study to ascertain that not more than two blood samples 
were withdrawn from each rat. Each study was conducted in triplicate. Rats of Group I, 
Group II and Group III received oral administration of, respectively, uncoated tablets or 74  G. Kaur, S. Jain and A. K. Tiwary:   
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tablets coated with admixtures containing 40:60 or 50:50 ratio of CH:CMTKP containing 
Eudragit L100-55 as binder. Rats of Group IV and V received uncoated tablets and tablets 
coated with IPC films comprising of 50:50 ratio of CH:CMTKP containing the same solution 
as binder. Similarly, rats of Group VI and VII received uncoated and tablets coated with 
admixtures containing 40:60 ratio of CH:CMTKP containing the same ratio of CH:CMTKP 
solution as binder. Blood samples (1 ml) were collected from retro orbital vein at 0, 1, 4, 8, 
12, 16 or 24 h, mixed with 40 µl of heparin and subjected to centrifugation at 4000 rpm for 
10 min. Upper layer was removed carefully and to 200 µl of plasma, methanol 20 µl and 
15 µl of internal standard solution (0.005% w/v clotrimazole in methanol) was added. Ethyl 
acetate (2 ml) was added and the microcentrifugation tubes were vortexed for 10 min. The 
tubes were then centrifuged at 4000 rpm for 10 min. The upper layer was aspirated, 
evaporated and reconstituted with 1mL of mobile phase. 20 µl of this solution was injected 
for HPLC analysis.  The protocol for this study was approved by the IAEC of Punjabi 
University, Patiala, India. 
Pharmacodynamic evaluation 
Sprague Dawley rats (200–250g) of 8–12 weeks age were used in the study. They were 
fed with standard laboratory chow diet and given water ad libitum. The experimental 
protocol was approved by Institutional Animal Ethics Committee of the Punjabi University, 
Patiala and the care and handling of the animals were in accordance with the National 
Institutes of Health guidelines.  
Induction of colonic inflammation  
The rats were fasted for 48 h before the induction of ulcerative colitis. 2,4,6 Trinitro 
benzene sulphonic acid (TNBS) (20mg) was dissolved in 0.25 ml of 50% v/v ethanol. This 
solution was instilled to each rat into the colonic part (7 cm from the anus) with the help of 
a catheter in order to induce ulcerative colitis [28]. The rats were monitored for three days 
without treatment to allow for the development of ulcerative colitis.  
Treatment of ulcerative colitis  
The rats that weighed 80–100% of their initial weight (before TNBS instillation) were 
selected after 3 days as the ulcerative colitis positive animals. These rats were divided into 
four groups. Rats of Group I, Group II received oral administration of, respectively, normal 
saline, uncoated tablets containing Eudragit L100-55 as binder. Group III and Group IV 
received oral administration of tablets coated with IPC films comprising 40:60 ratio of 
CH:CMTKP containing Eudragit L100-55 or respective ratio of CH:CMTKP solution as 
binder.  
All the groups received oral treatment once daily for five consecutive days. The colitis 
control group received 0.5 ml of normal saline instead of budesonide tablets.  
Assessment of colonic inflammation 
Colonic inflammation following rectal administration of TNBS as well as after different 
treatments (as detailed above) was assessed by the following parameters. 
Colon/ body weight ratio 
The rats were sacrificed on the sixth day (after five days of tablet administration) and distal   Chitosan-Carboxymethyl Tamarind Kernel Powder Interpolymer Complexation: …  75 
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colon segments (6 cm length) were resected, opened longitudinally and rinsed with iced 
phosphate buffer. The ratio of wet weight of the colon specimen to the body weight was 
calculated for each rat.  
Histopathological studies  
Tissue segments (1 cm in length) were fixed in 10% buffered formalin for histopathological 
studies. Histopathological studies were carried out using haematoxylin and eosin stains at 
Department of Pathology, Government Rajindera Hospital, Patiala, Punjab.  
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